Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Programs
Go To Specialties
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Jim Januzzi has been a member of the Massachusetts General Hospital Cardiology Division since 2000. He is the Hutter Family Professor of Medicine at Harvard Medical School and is on faculty at the Harvard Clinical Research Institute.Dr. Januzzi graduated first in his class from New York Medical College in 1994, and subsequently did a residency in Internal Medicine at the Brigham and Women's Hospital, followed by a cardiology and echocardiography fellowship at Massachusetts General Hospital. Since joining the staff at MGH, Dr. Januzzi is an active clinician, with a focus on heart failure and chronic coronary artery disease. He is an active teacher, and has a busy research program, with a specific focus on cardiac biomarker testing. He has published more than 600 manuscripts, and has edited 5 textbooks. He speaks widely on the topic of biomarker testing in heart disease and treatment of heart failure. He has served as the Cardiology Consultant to the Boston Red Sox since 2005. He is a Trustee of the American College of Cardiology, and an editor at two top cardiology journals.
View my most recent research
View my most recent publications at PubMed
Dr. Januzzi has published more than 500 peer reviewed publications, more than 100 review articles and book chapters and has edited 5 text books.
Results were released today from the first two clinical studies designed specifically to examine the effects of the heart drug sacubitril/valsartan on the structure and function of the failing heart.
A multi-institutional study led by a Massachusetts General Hospital physician supports the value of a biomarker to accurately diagnose or rule out acute heart failure in patients seen for shortness of breath at hospital emergency departments.
Eight can't miss sessions at the ACC.18 Scientific Sessions that include Mass General presenters.
Multibiomarker panels that include emerging novel biomarkers could surmount limitations of natriuretic peptides alone to improve personalized heart failure (HF) care.
Mass General physicians presented on the podium moderated sessions or showcased posters over 50 times at the American Heart Association 2017 Scientific Sessions.
In a large systematic surveys of the frequency and implications of supply/demand-related Type 2 MI a suite of risk factors has been identified to help ensure patients receive proper care.
Managing anticoagulation in nonvalvular atrial fibrillation can be improved using the 2017 American College of Cardiology’s Expert Consensus Decision Pathway.
Noninvasive models to predict the presence of coronary artery disease may help reduce the societal burden of CAD.
Heart failure specialists transition from outdated practice patterns to precision medicine and biomarker-based care to improve outcomes.
James Januzzi, MD, director of the MGH Cardiac Intensive Care Unit, was honored Sept. 8 in a ceremony at Harvard Medical
School (HMS) as the first incumbent of the Hutter Family Professorship in Medicine in the Field of Cardiology.
It was a perfect slide into second base. Keith Harris was safe – but a small abrasion on his left leg would prove otherwise.
At age 81, Roman W. DeSanctis, MD, is one of the hospital’s most veteran and most beloved physicians. To honor the legendary MGH cardiologist, the Roman W. DeSanctis, MD, Endowed Distinguished Scholar in Medicine has been established through the generosity of donor Joan Fu and several others.
Adding regular testing for blood levels of a biomarker of cardiac distress to standard care for the most common form of heart failure may significantly reduce the incidence of cardiovascular complications, a new MGH study finds.
Levels of a biomarker used in the diagnosis of heart attacks are almost universally elevated in patients who have undergone coronary-artery bypass grafting (CABG) and, when markedly elevated, powerfully predict the risk of complications.
Back to Top